RSS   Newsletter   Contact   Advertise with us
Post Online Media

Neon Therapeutics appoints Hugh O'Dowd as CEO

Neon TherapeuticsNeon Therapeutics, an immuno-oncology company, announced the appointment of Hugh O'Dowd to chief executive officer.
Article continues below

READ MORE Hugh Rosen joins Regulus board of directors

Mr. O'Dowd joins Neon Therapeutics from Novartis, where he spent more than 20 years in a variety of leadership roles, including chief commercial officer and head of global strategy of Novartis Oncology.

In this role, Mr. O'Dowd was responsible for global commercialization for the oncology portfolio, including Global Brand Leadership, Health Economics & Pricing, Early Phase Commercial Development, Strategic Capabilities, Business Development & Licensing and Global Sales Excellence.

Mr. O'Dowd began his career in pharmaceuticals in 1992 at Glaxo in sales, and moved to Novartis in 1996.

Following a career of increasing levels of responsibility in sales and marketing, he took a leading role in the commercialization of Gleevec before overseeing the entirety of Novartis Oncology commercialization and strategy in 2011.

Since 2015, Mr. O'Dowd was country president and general manager in the United Kingdom and Ireland.

Mr. O'Dowd holds a B.A. from Loyola University Chicago, and an MBA from the Kellstadt Graduate School of Business at DePaul University Chicago.

 LATEST MOVES FROM Massachusetts 


We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy